LQDA
Liquidia Corporation
NASDAQ · USHealthcareBiotechnology
$77.08-3.58%
Price as of Jul 20, 2026
LQDA financials
Liquidia Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $158.3M | $14.0M | $17.5M | $15.9M |
| Cost of revenue | $13.2M | $5.9M | $2.9M | $2.9M |
| Gross profit | $145.1M | $8.1M | $14.6M | $13.1M |
| Operating expenses | $196.5M | $129.4M | $88.0M | $51.8M |
| Operating income | -$51.4M | -$121.3M | -$73.4M | -$38.8M |
| Net income | -$68.9M | -$130.4M | -$78.5M | -$41.0M |
| EBITDA | -$43.2M | -$115.7M | -$70.1M | -$35.0M |
| Basic EPS | $-0.80 | $-1.66 | $-1.21 | $-0.67 |
| Diluted EPS | $-0.80 | $-1.66 | $-1.21 | $-0.67 |
| Balance sheet | ||||
| Cash & equivalents | $190.7M | $176.5M | $83.7M | $93.3M |
| Total assets | $327.9M | $230.3M | $118.3M | $129.2M |
| Total liabilities | $283.2M | $153.0M | $71.0M | $38.8M |
| Stockholders’ equity | $44.7M | $77.3M | $47.3M | $90.4M |
| Total debt | $197.9M | $122.4M | $49.5M | $24.5M |
| Net debt | $7.2M | -$54.1M | -$34.1M | -$68.8M |
| Cash flow | ||||
| Operating cash flow | -$35.7M | -$93.4M | -$41.6M | -$28.6M |
| Capital expenditure | -$4.3M | -$4.9M | -$1.3M | -$592.0K |
| Free cash flow | -$40.0M | -$98.4M | -$42.9M | -$29.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |